Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 928 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 
 


 
Table of Contents   
CASE REPORT  
Year : 2011  |  Volume : 22  |  Issue : 1  |  Page : 116-119
A rare association of Castleman's disease and nephrotic syndrome


Hematology and Pediatric Oncology Department, Hospital 20 Aout 1953, Casablanca, Morocco

Click here for correspondence address and email

Date of Web Publication30-Dec-2010
 

   Abstract 

Castleman's Disease (CD) is an uncommon and poorly understood disorder of lymph node hyperplasia of unknown etiology. This entity belongs to the atypical lymphoproliferative disorders, a heterogeneous group of diseases characterized by a hyperplastic reactive process involving the immune system. The association of the nephrotic syndrome and CD is extremely rare and their interrelation remains enigmatic. We report a case of CD of the hyaline-vascular type with unicentric localization complicated by nephrotic syndrome.

How to cite this article:
Tazi I, Rachid M, Quessar A, Benchekroun S. A rare association of Castleman's disease and nephrotic syndrome. Saudi J Kidney Dis Transpl 2011;22:116-9

How to cite this URL:
Tazi I, Rachid M, Quessar A, Benchekroun S. A rare association of Castleman's disease and nephrotic syndrome. Saudi J Kidney Dis Transpl [serial online] 2011 [cited 2019 Aug 25];22:116-9. Available from: http://www.sjkdt.org/text.asp?2011/22/1/116/74379

   Introduction Top


Castleman's Disease (CD) is an uncommon and poorly understood disorder of lymph node hyperplasia with unknown etiology that was described first in 1956. [1] This entity belongs to the atypical lymphoproliferative disorders, a heterogeneous group of diseases characterized by a hyperplastic reactive process involving the immune system. [2],[3] CD is classified into two clinical subtypes: a localized (or unicentric) subtype and a multicentric subtype. Localized disease manifests as a solitary mass, which may be well circumscribed or infiltrative. It is associated with lymphadenopathy confined to one lymph node or nodal area, [4] and usually follows a benign course. Multicentric disease carries a worse prognosis, and subsequent infection or malignancy may lead to death. [4] CD can also be classified into two major histolo­gical subtypes: a hyaline-vascular subtype and a plasma cell subtype. The hyaline-vascular subtype is more common and contains nume­rous regressively transformed follicles and associated vascular proliferation. The plasma cell type contains hyperplastic follicles and marked plasma cell proliferation in the inter­follicular region. A mixed form, also called the hyaline-vascular-plasma cell subtype, is unco­mmon. [5] CD may occur anywhere along the lymphatic chain, although the mediastinum is the most common location (70%). Extratho­racic sites have been reported in the neck, axilla, pelvis and retroperitoneum. [5]

We report here an unusual case of CD of the hyaline-vascular type with unicentric localiza­tion complicated by nephrotic syndrome.


   Case Report Top


A 45-year-old Moroccan man was admitted to our institution, with a 2-year history of cervical lymphadenopathy, progressive fatigue, poor appetite and loss of body weight of 6 kg without fever. His past medical history was significant for insulin-dependent type-2 diabe­tes mellitus. He was afebrile and had pulse of 96 per minute, the blood pressure was 120/80 mmHg, and respiration was 22 per minute. No jaundice, skin rashes, or petechiae were pre­sent. The cervical lymph nodes were enlarged, 1-3 cm in diameter, firm, mobile, and not ten­der. Rest of the physical examination was un­remarkable.

Laboratory investigations showed hemoglo­bin of 13 g/dL, mean cell volume (MCV) of 83 fL, white cell count of 4700/L and platelet of 164,000/L. The bleeding time and coagula­tion time were normal. Erythrocyte sedimen­tation rate was 40 mm/1 h and C-reactive pro­tein was 12 mg/L. Renal investigation and liver tests were normal. Hepatitis B and C serology and HIV serology were negative. Chest X-ray was normal. Ultrasound examination of the abdomen showed normal kidneys, liver, spleen and pancreas. Computed tomography (CT) scan of the abdomen and the chest was normal. Histopathological examination of the surgical sample revealed hyaline-vascular CD (giant lymph node hyperplasia). Bone marrow biopsy was negative for malignancy. Activity of lac­tate dehydrogenase was normal.

The patient received steroids orally at a dose of 15 mg of prednisone per day. He developed impaired glucose tolerance which was con­trolled with insulin. One year after the start of steroid therapy, the patient was admitted to our hospital with complaints of vomiting and pro­found peripheral edema of several days dura­tion. Peripheral edema was present. The lung fields were clear. Abdominal examination re­vealed ascites, without splenomegaly.

Checkups for possible propagation of CD, including the activity of lactate dehydrogenase, chest X-ray and abdominal ultrasonography, were normal.

The 24-hour urinary protein was 7.2 g and the serum cholesterol and albumin levels were 9.1 mmol/L and 19 g/L, respectively. Serum creatinine and serum urea were normal. Urine analysis did not show hematuria or leukocy­turia. Cryoglobulins were also absent. Diabetic retinopathy was absent on ophthalmoscopic examination. A renal biopsy was performed. The findings were consistent with membra­nous glomerulonephritis.

Intravenous methylprednisolone, 1 g/day for 3 days, was administered, followed by oral prednisone, 50 mg/day for 2 months. The neph­rotic syndrome disappeared after 3 months of treatment. Corticosteroids were slowly tapered down and stopped 12 months after their initia­tion. Since that remission, at 2 years of follow­up, still the nephrotic syndrome is in remission, nor has the CD relapsed.


   Discussion Top


CD is known as a giant lymph node hyper­plasia which was first described in 1956 by Castleman. CD is a rare clinicopathologic entity classified among atypical lymphoproliferative disorders. [1] Since its initial description, CD has been redefined from a localized tumor-like mass of lymphoid tissue, considered to be ha­martomatous, to a systemic disease with gene­ral manifestations and multiple organ involve­ment. Our patient had a classical picture of the unicentric CD. He had a cervical localization of the plasma cell type which remained loca­lized for one year. He had a long history of illness and the nephrotic syndrome developed two years after the discovery of the cervical lesion. The extremely rare association between CD and nephrotic syndrome prompted us to report this case.

Humpherys et al described the first patient, an 18-year-old girl whose nephrotic syndrome remitted promptly after the removal of a me­senteric mass which showed angiofollicular lymph node hyperplasia of the plasma cell type. [9] The renal biopsy showed minimal change nephropathy. Weisenburger [10] described a 51­year-old man who had a membranous nephro­pathy associated with multicentric angiofolli­cular lymph node hyperplasia, also of the plas­ma cell type. The nephrotic syndrome in that patient apparently developed one year after the onset of the lymph node enlargements similar to our case.

Although the pathogenesis of CD is entirely unknown, several investigators consider the localized plasma cell form to be an inflam­matory response to an unknown antigenic stimulus. The plasma cells in the lymph node would represent an exuberant B-cell response that results in the local production of high levels of antibodies. [11]

Nephrotic syndrome is a very rare compli­cation of CD. Only a few cases have been described. [12],[13],[14] Other reported forms of renal involvement in CD are rare and heterogeneous and include minimal-change disease, membra­nous GN, membranoproliferative GN, mesan­gial proliferative GN and interstitial nephritis. [15],[16]

As currently understood, CD is considered to be a heterogeneous entity related to conditions of immune deregulation. In this respect, it is interesting that various disorders of the im­mune system may be characterized by Castle­man-like histological changes, such as infec­tions (HIV) and primary auto-immune diseases (systemic lupus erythematosus, POEMS syn­drome, etc.). [17] Moreover, nephrotic syndrome appeared after the CD was diagnosed and subsequent to lymph node regression. Sugges­ting the triggering of the inflammatory res­ponse with consequent autoimmune organ ma­nifestations.

There are some unusual features about the patient, which make one hesitate to attribute the nephrotic syndrome to diabetic nephro­pathy. His diabetes developed two years be­fore renal biopsy. The nephrotic syndrome in diabetic patients with such a short history of disease is unusual. The absence of retinopathy and a significant degree of hyaline arterioscle­rosis from diabetic patients with overt neph­rotic syndrome is again exceptional.

There is a strong possibility that his renal lesions had some more direct relation with his underlying long history of angiofollicular hy­perplasia and immunological disturbance.

Lui et al have demonstrated an association of CD with excess production of the cytokine interleukin-6 (IL-6). [15] IL-6 is a pleiotrophic cytokine produced by several cell types, inclu­ding activated monocytes, B cells, endothelial cells, fibroblasts and mesangial cells. It has a panoply of biological effects, including a ma­jor regulatory effect on acute-phase response in humans. Large amounts of IL-6 were shown to be produced at the germinal centers of hyper­plastic lymph nodes from patients with CD and clinical improvement was observed along with decreases in IL-6 levels after the removal of the involved lymph nodes [15] or treatment with anti-IL-6 antibodies. [18] Corticosteroid therapy has also been shown to reduce IL-6 levels.

The treatment of CD and the possible re­versal of both amyloidosis and the nephrotic syndrome are controversial issues, based es­sentially on case reports, since controlled cli­nical studies are lacking because of the rarity of the disease. In some reports on monocentric forms, it was shown that the surgical removal of the lymph node mass was curative [11],[19] and led to the regression of the nephrotic syndrome and of amyloidosis, as detected by abdominal fat aspiration biopsy. [11]

However, Keven et al, although confirming the regression of the nephritic syndrome after excision of an abdominal lymph node, docu­mented no regression of renal amyloid depo­sits, one year after surgery. [12] Some reports do­cumented no regression of the nephritic syndrome after lymph-node excision, [20],[21] whereas some showed regression with colchicine the­rapy. [21] Current approaches include high-dose corticosteroids and in some cases the addition of antineoplastic agents, with poor clinical benefits. [4]

 
   References Top

1.Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyper-plasia resembling thymona. Cancer 1956; 9:822-30.   Back to cited text no. 1
[PUBMED]    
2.Frizzera G. Immunosuppression, autoimmunity, and lymphoproliferative disorders. Hum Pathol 1994;25:627-9.  Back to cited text no. 2
[PUBMED]    
3.Krishnan J, Danon AD, Frizzera G. Re-active lymphoadenopathies and atypical lymphoproli­ferative disorders. Am J Clin Pathol 1993;99: 385-96.  Back to cited text no. 3
[PUBMED]    
4.Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, et al. The management of unicentric and multicentric Castleman's disease: A report of 16 cases and a review of the literature. Cancer 1999;85:706-17.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Keller AR, Hockholtzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of mediastinum and other locations. Cancer 1972; 29:670-83.  Back to cited text no. 5
    
6.Chen XF, Li YH, Zhang Y, et al. Local Castleman's disease: A report of a 17 cases with literature review. Ai Zheng 2008;27(3): 315-8.  Back to cited text no. 6
    
7.Dispenzieri A. Castleman's disease. Cancer Treat Res 2008;142:293-330.  Back to cited text no. 7
[PUBMED]    
8.Sharma R, Seth R, Thavaraj V, et al. Multi­centric Castleman's disease in two cases. Indian J Pediatr 2007;74(12):1116-20.  Back to cited text no. 8
    
9.Humpherys SR, Holly KE, Smith LH, Mcllrath DC Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with neph­rotic syndrome. Mayo Clinic Proc 1975;50: 317-21.  Back to cited text no. 9
    
10.Weisenburger DD. Membranous nephro-pathy. Its association with multicentric angiofollicular lymph node hyperplasia. Arch Pathol Lab Med 1979;103:591-4.  Back to cited text no. 10
[PUBMED]    
11.Perfetti V, Bellotti V, Maggi A, et al. Re­versal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol 1994;46(3):189-93.  Back to cited text no. 11
    
12.Keven K, Nergiozogh G, Ales K, et al. Re­mission of nephrotic syndrome after removal of localized Castleman's disease. Am J Kidney Dis 2000;35:1207-11.  Back to cited text no. 12
    
13.Ruggieri G, Barsotti P, Coppia G, et al. Mem­branous nephropathy associated with giant lymph node hyperplasia. Am J Nephrol 1990;10:323-8.  Back to cited text no. 13
    
14.Combe C, Bouchet JL, Potaux L, et al. Castle­man's disease and glomerular neph-ropathy (apropos of 1 case). Nephrologie 1989;10:163-6.  Back to cited text no. 14
[PUBMED]    
15.Lui SL, Chan KW, Li FK, et al. Castle-man's disease and mesangial proliferative glomerulo­nephritis: The role of interleukin-6. Nephron 1998;78:323-7.  Back to cited text no. 15
[PUBMED]  [FULLTEXT]  
16.Akimoto H, Shirai M, Usutani S, et al. Mem­branoproliferative glomerulonephritis-like lesion with fibrillary deposition associated with mul­ticentric Castleman's disease. Jpn J Nephrol 1998;40:301-8.  Back to cited text no. 16
    
17.Frizzera G, Massarelli G, Banks PM, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol 1983;7:211-31.  Back to cited text no. 17
[PUBMED]    
18.Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by momoclonal anti­interleukin-6 antibody. N Engl J Med 1994; 330:602-5.  Back to cited text no. 18
[PUBMED]  [FULLTEXT]  
19.Kazes I, Deray G, Jacobs C. Castleman's di­sease and renal amyloidosis. Ann Intern Med 1995;71:463-4.  Back to cited text no. 19
    
20.Arinsoy T, Yilmaz M, Ataoglu O, et al. Castle­man's disease with renal amyloidosis and nephrotic syndrome. Nephrol Dial Transplant 1997;12:2713-6.  Back to cited text no. 20
    
21.Paydas S, Gonlusen G, Saliker Y. Regression of nephrotic syndrome with colchicines the­rapy secondary to amyloidosis with associated Castleman's disease. Nephron 1995;71:463-4.  Back to cited text no. 21
    

Top
Correspondence Address:
I Tazi
Hematology and Pediatric Oncology Department, Hospital 20 Aout 1953, Rue Lahcen Laarjoune, Casablanca
Morocco
Login to access the Email id


PMID: 21196625

Rights and Permissions



This article has been cited by
1 Parapharengeal unicentric castleman disease with nephrotic syndrome
Saghafi, H. and Aghaali, M. and Haghighi, S.
Iranian Journal of Kidney Diseases. 2013; 7(4): 316-318
[Pubmed]
2 Castleman disease with preceding symptoms of nephrotic syndrome
Li, Y. and Tong, H. and Mao, L. and Wang, H. and Jin, J.
Clinical Nephrology. 2012; 78(6): 508-510
[Pubmed]
3 Unicentric castlemanæs disease located in the lower extremity: A case report
Schaefer, I.-M. and Günnel, H. and Schweyer, S. and Korenkov, M.
BMC Cancer. 2011; 11(352)
[Pubmed]



 

Top
   
 
 
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  
 


 
    Abstract
    Introduction
    Case Report
    Discussion
    References
 

 Article Access Statistics
    Viewed2586    
    Printed80    
    Emailed0    
    PDF Downloaded541    
    Comments [Add]    
    Cited by others 3    

Recommend this journal